Radnor Capital Management LLC Acquires 18,600 Shares of Edwards Lifesciences Co. (NYSE:EW)

Radnor Capital Management LLC lifted its position in Edwards Lifesciences Co. (NYSE:EW) by 358.8% in the third quarter, Holdings Channel.com reports. The institutional investor owned 23,784 shares of the medical research company’s stock after buying an additional 18,600 shares during the period. Radnor Capital Management LLC’s holdings in Edwards Lifesciences were worth $1,570,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Crewe Advisors LLC acquired a new position in shares of Edwards Lifesciences during the 1st quarter worth about $28,000. First Community Trust NA bought a new position in shares of Edwards Lifesciences during the second quarter worth approximately $29,000. Webster Bank N. A. bought a new position in Edwards Lifesciences in the second quarter valued at approximately $39,000. Peoples Bank KS bought a new position in Edwards Lifesciences in the third quarter valued at approximately $40,000. Finally, Versant Capital Management Inc boosted its position in Edwards Lifesciences by 206.3% in the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock valued at $45,000 after buying an additional 326 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on EW. The Goldman Sachs Group cut their price target on shares of Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Stifel Nicolaus cut their price target on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating on the stock in a report on Thursday, July 25th. TD Cowen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their price target for the stock from $100.00 to $70.00 in a report on Thursday, July 25th. Royal Bank of Canada dropped their target price on shares of Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Finally, Barclays dropped their price target on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Seventeen equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $75.67.

Insiders Place Their Bets

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total transaction of $347,550.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,262,521.36. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,250 shares of company stock valued at $2,746,988. 1.27% of the stock is owned by insiders.

Edwards Lifesciences Stock Up 0.3 %

Shares of Edwards Lifesciences stock opened at $66.69 on Wednesday. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The firm’s 50-day moving average is $67.81 and its two-hundred day moving average is $77.26. The stock has a market cap of $40.17 billion, a price-to-earnings ratio of 9.62, a PEG ratio of 3.80 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 22.56%. The company’s revenue was up 8.9% compared to the same quarter last year. During the same period last year, the business earned $0.59 EPS. As a group, research analysts expect that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.